Myo-inositol reduces ?-catenin activation in colitis

Emily M. Bradford; Corey A. Thompson; Tatiana Goretsky; Guang Yu Yang; Luz M. Rodriguez; Linheng Li; Terrence A. Barrett

doi:10.3748/wjg.v23.i28.5115

Myo-inositol reduces ?-catenin activation in colitis

Emily M. Bradford, Corey A. Thompson, Tatiana Goretsky, Guang Yu Yang, Luz M. Rodriguez, Linheng Li, Terrence A. Barrett^*

^*Corresponding author for this work

Pathology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

AIM To assess Dietary myo-inositol in reducing stem cell activation in colitis, and validate p?-cateninS552 as a biomarker of recurrent dysplasia. METHODS We examined the effects of Dietary myo-inositol treatment on inflammation, p?-cateninS552 and pAkt levels by histology and western blot in IL-10-/- and dextran soDium sulfate-treated colitic mice. AdDitionally, we assessed nuclear p?-cateninS552 in patients treated with myo-inositol in a clinical trial, and in patients with and without a history of colitis-induced dysplasia. RESULTS In mice, p?-cateninS552 staining faithfully reported the effects of myo-inositol in reducing inflammation and intestinal stem cell activation. In a pilot clinical trial of myo-inositol administration in patients with a history of low grade dysplasia (LGD), two patients had reduced numbers of intestinal stem cell activation compared to the placebo control patient. In humans, p?-cateninS552 staining Discriminated ulcerative colitis patients with a history of LGD from those with benign Disease. CONCLUSION Enumerating crypts with increased numbers of p?- cateninS552 - positive cells can be utilized as a biomarker in colitis-associated cancer chemoprevention trials.

Original language	English (US)
Pages (from-to)	5115-5126
Number of pages	12
Journal	World Journal of Gastroenterology
Volume	23
Issue number	28
DOIs	https://doi.org/10.3748/wjg.v23.i28.5115
State	Published - Jul 28 2017

Keywords

Biomarker
Chemoprevention
Colitis-associated cancer
Dysplasia
Stem cell

ASJC Scopus subject areas

Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3748/wjg.v23.i28.5115

Cite this

@article{9837b559901949ff845a46c7e49f1ba7,

title = "Myo-inositol reduces ?-catenin activation in colitis",

abstract = "AIM To assess Dietary myo-inositol in reducing stem cell activation in colitis, and validate p?-cateninS552 as a biomarker of recurrent dysplasia. METHODS We examined the effects of Dietary myo-inositol treatment on inflammation, p?-cateninS552 and pAkt levels by histology and western blot in IL-10-/- and dextran soDium sulfate-treated colitic mice. AdDitionally, we assessed nuclear p?-cateninS552 in patients treated with myo-inositol in a clinical trial, and in patients with and without a history of colitis-induced dysplasia. RESULTS In mice, p?-cateninS552 staining faithfully reported the effects of myo-inositol in reducing inflammation and intestinal stem cell activation. In a pilot clinical trial of myo-inositol administration in patients with a history of low grade dysplasia (LGD), two patients had reduced numbers of intestinal stem cell activation compared to the placebo control patient. In humans, p?-cateninS552 staining Discriminated ulcerative colitis patients with a history of LGD from those with benign Disease. CONCLUSION Enumerating crypts with increased numbers of p?- cateninS552 - positive cells can be utilized as a biomarker in colitis-associated cancer chemoprevention trials.",

keywords = "Biomarker, Chemoprevention, Colitis-associated cancer, Dysplasia, Stem cell",

author = "Bradford, {Emily M.} and Thompson, {Corey A.} and Tatiana Goretsky and Yang, {Guang Yu} and Rodriguez, {Luz M.} and Linheng Li and Barrett, {Terrence A.}",

note = "Funding Information: Supported by Veterans Affairs Merit Award, No. IO1CX001353 (to Barrett TA); National Institutes of Health, No. 2R01DK095662-06A1 (to Barrett TA); the National Cancer Institute at the National Institutes of Health, No. N01-CN-35157 (to Bergan R); the Training Program in Oncogenesis and Developmental Biology through the National Cancer Institute, No. NCI T32 CA080621 (to Bradford EM); an Institutional Development Award from the National Institute of General MeDical Sciences of the National Institutes of Health, No. 8 P20GM103527-05; and American Physiological Society STEP-UP Fellowship (to Thompson CA). Publisher Copyright: {\textcopyright} The Author(s) 2017.",

year = "2017",

month = jul,

day = "28",

doi = "10.3748/wjg.v23.i28.5115",

language = "English (US)",

volume = "23",

pages = "5115--5126",

journal = "World Journal of Gastroenterology",

issn = "1007-9327",

publisher = "WJG Press",

number = "28",

}

TY - JOUR

T1 - Myo-inositol reduces ?-catenin activation in colitis

AU - Bradford, Emily M.

AU - Thompson, Corey A.

AU - Goretsky, Tatiana

AU - Yang, Guang Yu

AU - Rodriguez, Luz M.

AU - Li, Linheng

AU - Barrett, Terrence A.

N1 - Funding Information: Supported by Veterans Affairs Merit Award, No. IO1CX001353 (to Barrett TA); National Institutes of Health, No. 2R01DK095662-06A1 (to Barrett TA); the National Cancer Institute at the National Institutes of Health, No. N01-CN-35157 (to Bergan R); the Training Program in Oncogenesis and Developmental Biology through the National Cancer Institute, No. NCI T32 CA080621 (to Bradford EM); an Institutional Development Award from the National Institute of General MeDical Sciences of the National Institutes of Health, No. 8 P20GM103527-05; and American Physiological Society STEP-UP Fellowship (to Thompson CA). Publisher Copyright: © The Author(s) 2017.

PY - 2017/7/28

Y1 - 2017/7/28

N2 - AIM To assess Dietary myo-inositol in reducing stem cell activation in colitis, and validate p?-cateninS552 as a biomarker of recurrent dysplasia. METHODS We examined the effects of Dietary myo-inositol treatment on inflammation, p?-cateninS552 and pAkt levels by histology and western blot in IL-10-/- and dextran soDium sulfate-treated colitic mice. AdDitionally, we assessed nuclear p?-cateninS552 in patients treated with myo-inositol in a clinical trial, and in patients with and without a history of colitis-induced dysplasia. RESULTS In mice, p?-cateninS552 staining faithfully reported the effects of myo-inositol in reducing inflammation and intestinal stem cell activation. In a pilot clinical trial of myo-inositol administration in patients with a history of low grade dysplasia (LGD), two patients had reduced numbers of intestinal stem cell activation compared to the placebo control patient. In humans, p?-cateninS552 staining Discriminated ulcerative colitis patients with a history of LGD from those with benign Disease. CONCLUSION Enumerating crypts with increased numbers of p?- cateninS552 - positive cells can be utilized as a biomarker in colitis-associated cancer chemoprevention trials.

AB - AIM To assess Dietary myo-inositol in reducing stem cell activation in colitis, and validate p?-cateninS552 as a biomarker of recurrent dysplasia. METHODS We examined the effects of Dietary myo-inositol treatment on inflammation, p?-cateninS552 and pAkt levels by histology and western blot in IL-10-/- and dextran soDium sulfate-treated colitic mice. AdDitionally, we assessed nuclear p?-cateninS552 in patients treated with myo-inositol in a clinical trial, and in patients with and without a history of colitis-induced dysplasia. RESULTS In mice, p?-cateninS552 staining faithfully reported the effects of myo-inositol in reducing inflammation and intestinal stem cell activation. In a pilot clinical trial of myo-inositol administration in patients with a history of low grade dysplasia (LGD), two patients had reduced numbers of intestinal stem cell activation compared to the placebo control patient. In humans, p?-cateninS552 staining Discriminated ulcerative colitis patients with a history of LGD from those with benign Disease. CONCLUSION Enumerating crypts with increased numbers of p?- cateninS552 - positive cells can be utilized as a biomarker in colitis-associated cancer chemoprevention trials.

KW - Biomarker

KW - Chemoprevention

KW - Colitis-associated cancer

KW - Dysplasia

KW - Stem cell

UR - http://www.scopus.com/inward/record.url?scp=85026503516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026503516&partnerID=8YFLogxK

U2 - 10.3748/wjg.v23.i28.5115

DO - 10.3748/wjg.v23.i28.5115

M3 - Article

C2 - 28811707

AN - SCOPUS:85026503516

SN - 1007-9327

VL - 23

SP - 5115

EP - 5126

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

IS - 28

ER -

Myo-inositol reduces ?-catenin activation in colitis

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this